Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia - GlobeNewswire
Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia GlobeNewswire
... ~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial ...
Comments
Post a Comment